The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.
The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.25 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches.
The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.56 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence.
The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. oncology treatment by increasing costs for temozolomide generics and tumor-treating fields (TTF) devices imported from India and Israel, potentially worsening survival outcomes and raising neuro-oncology department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.
The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels-federal, state, or local-towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.
Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.
In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. This acquisition is intended to enhance Novartis's pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors like gliomas. Mariana Oncology, a US-based preclinical-stage biotechnology firm, focuses on developing therapeutics for gliomas.
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adult Malignant Glioma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on adult malignant glioma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adult malignant glioma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adult malignant glioma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types
- 2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies
- 3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users
- Subsegments:
- 1) By Glioblastoma Multiforme: Standard Treatments; Experimental Therapies
- 2) By Anaplastic Astrocytoma: Chemotherapy Options; Targeted Therapies
- 3) By Anaplastic Oligodendroglioma: Radiation Therapy; Combination Therapies
- 4) By Anaplastic Oligoastrocytoma: Surgical Interventions; Adjuvant Therapies
- 5) By Other Types: Rare Gliomas; Emerging Therapies
- Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Allergan plc; AbbVie Inc.; Novartis AG; Bayer AG; Merck & Co Inc.; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Abbott Laboratories; AstraZeneca plc; Eli Lilly and Company; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; GT Medical Technologies Inc.; Lupin Limited; Mylan NV; Sanofi SA; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Genetech Inc.; Amneal Pharmaceuticals LLC; Emcure Pharmaceuticals Limited; Novocure Ltd.; Arbour Pharmaceuticals LLC; Basilea Pharmaceuticals Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Adult Malignant Glioma Therapeutics Market Characteristics
3. Adult Malignant Glioma Therapeutics Market Trends And Strategies
4. Adult Malignant Glioma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Adult Malignant Glioma Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Adult Malignant Glioma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Adult Malignant Glioma Therapeutics Market Growth Rate Analysis
- 5.4. Global Adult Malignant Glioma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Adult Malignant Glioma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Adult Malignant Glioma Therapeutics Total Addressable Market (TAM)
6. Adult Malignant Glioma Therapeutics Market Segmentation
- 6.1. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Oligoastrocytoma
- Other Types
- 6.2. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Targeted Therapy
- Radiotherapy
- Other Therapies
- 6.3. Global Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Cancer And Radiation Therapy Centers
- Other End Users
- 6.4. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Glioblastoma Multiforme, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Standard Treatments
- Experimental Therapies
- 6.5. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Astrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy Options
- Targeted Therapies
- 6.6. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligodendroglioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Radiation Therapy
- Combination Therapies
- 6.7. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligoastrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgical Interventions
- Adjuvant Therapies
- 6.8. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rare Gliomas
- Emerging Therapies
7. Adult Malignant Glioma Therapeutics Market Regional And Country Analysis
- 7.1. Global Adult Malignant Glioma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Adult Malignant Glioma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Adult Malignant Glioma Therapeutics Market
- 8.1. Asia-Pacific Adult Malignant Glioma Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Adult Malignant Glioma Therapeutics Market
- 9.1. China Adult Malignant Glioma Therapeutics Market Overview
- 9.2. China Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Adult Malignant Glioma Therapeutics Market
- 10.1. India Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Adult Malignant Glioma Therapeutics Market
- 11.1. Japan Adult Malignant Glioma Therapeutics Market Overview
- 11.2. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Adult Malignant Glioma Therapeutics Market
- 12.1. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Adult Malignant Glioma Therapeutics Market
- 13.1. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Adult Malignant Glioma Therapeutics Market
- 14.1. South Korea Adult Malignant Glioma Therapeutics Market Overview
- 14.2. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Adult Malignant Glioma Therapeutics Market
- 15.1. Western Europe Adult Malignant Glioma Therapeutics Market Overview
- 15.2. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Adult Malignant Glioma Therapeutics Market
- 16.1. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Adult Malignant Glioma Therapeutics Market
- 17.1. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Adult Malignant Glioma Therapeutics Market
- 18.1. France Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Adult Malignant Glioma Therapeutics Market
- 19.1. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Adult Malignant Glioma Therapeutics Market
- 20.1. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Adult Malignant Glioma Therapeutics Market
- 21.1. Eastern Europe Adult Malignant Glioma Therapeutics Market Overview
- 21.2. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Adult Malignant Glioma Therapeutics Market
- 22.1. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Adult Malignant Glioma Therapeutics Market
- 23.1. North America Adult Malignant Glioma Therapeutics Market Overview
- 23.2. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Adult Malignant Glioma Therapeutics Market
- 24.1. USA Adult Malignant Glioma Therapeutics Market Overview
- 24.2. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Adult Malignant Glioma Therapeutics Market
- 25.1. Canada Adult Malignant Glioma Therapeutics Market Overview
- 25.2. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Adult Malignant Glioma Therapeutics Market
- 26.1. South America Adult Malignant Glioma Therapeutics Market Overview
- 26.2. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Adult Malignant Glioma Therapeutics Market
- 27.1. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Adult Malignant Glioma Therapeutics Market
- 28.1. Middle East Adult Malignant Glioma Therapeutics Market Overview
- 28.2. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Adult Malignant Glioma Therapeutics Market
- 29.1. Africa Adult Malignant Glioma Therapeutics Market Overview
- 29.2. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Adult Malignant Glioma Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Adult Malignant Glioma Therapeutics Market Competitive Landscape
- 30.2. Adult Malignant Glioma Therapeutics Market Company Profiles
- 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis
31. Adult Malignant Glioma Therapeutics Market Other Major And Innovative Companies
- 31.1. AbbVie Inc.
- 31.2. Novartis AG
- 31.3. Bayer AG
- 31.4. Merck & Co Inc.
- 31.5. GlaxoSmithKline plc
- 31.6. Bristol-Myers Squibb Company
- 31.7. Abbott Laboratories
- 31.8. AstraZeneca plc
- 31.9. Eli Lilly and Company
- 31.10. Amgen Inc.
- 31.11. Teva Pharmaceutical Industries Ltd.
- 31.12. GT Medical Technologies Inc.
- 31.13. Lupin Limited
- 31.14. Mylan NV
- 31.15. Sanofi SA
32. Global Adult Malignant Glioma Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market
34. Recent Developments In The Adult Malignant Glioma Therapeutics Market
35. Adult Malignant Glioma Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Adult Malignant Glioma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Adult Malignant Glioma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Adult Malignant Glioma Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
